Integrated Biotherapeutics, Inc.

Leland Stanford Junior University

University System of Maryland

Razi Holdings, Inc.

Frederick Wayne Holtsberg

Mohammad Javad Aman

Rajan Prasad Adhikari

Hatice Karauzum

Sergey Shulenin

Katie A Howell

Yuxing Li

Zhen-Yong Keck

Steven K H Foung

Sven G Enterlein

Xuelian Zhao

This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.

Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop

The disclosure provides non-human primate-derived binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.

Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins

The present disclosure provides immunogenic compositions useful in prevention and treatment ofinfection. In particular, the disclosure provides delta toxin and phenol-soluble modulin peptides as well as mutants, fragments, variants or derivatives thereof. The disclosure further provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal proteins, e.g., DT, PSM, alpha hemolysin, leukocidin, superantigen, or any fragments, variants, derivatives, or mutants thereof fused together as a single polypeptide in any order.

Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

Growing community of inventors

Taneytown, MD, United States of America

Frederick Wayne Holtsberg